Literature DB >> 31971024

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.

Naim Alkhouri1.   

Abstract

Entities:  

Keywords:  NAFLD; nash; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; obeticholic acid; regenerate trial; type-2 diabetes

Mesh：

Year:  2020        PMID： 31971024     DOI： 10.1080/13543784.2020.1721167

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


× No keyword cloud information.
  1 in total

1.  Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice.

Authors:  Tulasi Yadati; Tom Houben; Albert Bitorina; Yvonne Oligschlaeger; Marion J Gijbels; Ronny Mohren; Dieter Lütjohann; Princy Khurana; Sandeep Goyal; Aditya Kulkarni; Jan Theys; Berta Cillero-Pastor; Ronit Shiri-Sverdlov
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.